MORPHOSYS AG
MORPHOSYS AG (DELISTED)
Aktie · DE0006632003 · 663200 (XETR)
Übersicht Finanzkennzahlen
Kein Kurs
n/a

Performance

Heute Woche Monat 3 Monate 6 Monate 1 Jahr 5 Jahre
- - - - 0,00 % 0,52 % -40,75 %

Firmenprofil zu MORPHOSYS AG Aktie

MorphoSys AG, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic antibodies for patients suffering from cancer and autoimmune diseases in the United States. It offers Tafasitamab, an antibody for the treatment of B cell malignancies, including diffuse large B-cell lymphoma, follicular lymphoma, and marginal zone lymphoma. The company also develops Pelabresib, a small molecule that is in Phase II clinical trial to treat myelofibrosis; Felzartamab, an antibody directed against CD38, which is in Phase I/II clinical trials for the treatment of anti-PLA2R-positive membranous nephropathy, an autoimmune disease; and CPI-0209, a small molecule that is in Phase I/II designed to promote anti-tumor activity by inhibiting EZH2. In addition, it develops Gantenerumab, an antibody for the treatment of Alzheimer's diseases through its pharmaceutical partners; Otilimab, an antibody for rheumatoid arthritis; Tremfya, an antibody to treat psoriasis, psoriatic arthritis, and palmoplantar pustulosis; and MOR210/TJ210, an antibody to treat immuno-oncology and autoimmune diseases. MorphoSys AG has a regional licensing agreement with I-Mab Biopharma to develop and commercialize felzartamab in China, Taiwan, Hong Kong, and Macau; a strategic alliance with the LEO Pharma; a joint collaboration and license agreement with Incyte Corporation to develop and commercialize MorphoSys investigational compound tafasitamab; and a clinical collaboration with Incyte Corporation and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was founded in 1992 and is headquartered in Planegg, Germany.

Investierte Fonds

Folgende Fonds haben in investiert: MORPHOSYS AG investiert:

Fonds
iShares TecDAX® UCITS ETF (DE) EUR (Dist)
Vol. in Mio
3,72
Anteil (%)
1,18 %
Fonds
iShares TecDAX® UCITS ETF (DE) EUR (Acc)
Vol. in Mio
12.878,53
Anteil (%)
1,18 %
Fonds
iShares EURO STOXX Small UCITS ETF EUR (Dist)
Vol. in Mio
6.502,84
Anteil (%)
0,51 %
Fonds
iShares MDAX® UCITS ETF (DE) EUR (Dist)
Vol. in Mio
12,61
Anteil (%)
0,46 %
Fonds
iShares MSCI EMU Small Cap UCITS ETF EUR (Acc)
Vol. in Mio
2.364,24
Anteil (%)
0,28 %

Unternehmensdaten

Name MORPHOSYS AG
Firma MorphoSys AG
Website https://www.morphosys.com
Heimatbörse XETR XETRA
WKN 663200
ISIN DE0006632003
Wertpapierart Aktie
Sektor Healthcare
Branche Biotechnology
CEO Mr. Arkadius Pichota M.B.A., Ph.D.
Marktkapitalisierung 3 Mrd.
Land Deutschland
Währung EUR
Mitarbeiter 0,5 T
Adresse Semmelweisstrasse 7, 82152 Planegg
IPO Datum 1999-03-10

Ticker Symbole

Name Symbol
Frankfurt MOR.F
XETRA MOR.DE

Weitere Aktien

Investoren die MORPHOSYS AG die halten, haben auch folgende Aktien im Depot:
ALPHABET INC - CLASS A
ALPHABET INC - CLASS A Aktie
AMAZON.CO INC
AMAZON.CO INC Aktie
BAYER AG
BAYER AG Aktie
INFINEON TECHNOLOGIESLOGIES AG
INFINEON TECHNOLOGIESLOGIES AG Aktie
ISHSIV-MSCI CHINA DL A
ISHSIV-MSCI CHINA DL A ETF
LYXOR EURO GOVERNMENT BOND (DR) UCITS ETF - ACC
LYXOR EURO GOVERNMENT BOND (DR) UCITS ETF - ACC ETF
META PLATFORMS INC
META PLATFORMS INC Aktie
MICROSOFT CORP
MICROSOFT CORP Aktie
NAUTICUS ROBOTI. DL-,0001
NAUTICUS ROBOTI. DL-,0001 Aktie
PAYPAL INC
PAYPAL INC Aktie
SAP SE
SAP SE Aktie
TESLA INC
TESLA INC Aktie
VERMILION ENERGY INC
VERMILION ENERGY INC Aktie
WALT DISNEY INC
WALT DISNEY INC Aktie
Die Finanzplattform MoneyPeak trackt und analysiert Investitionen und Portfolios. Vom Wertpapier-Depot bis zum Crypto-Kauf.
Nützlich, simpel und kostenlos. Aktien, ETF, ETC, ETN, Indizes, Fonds, Anleihen, Zertifikate, Währungen, Optionen, Bezugsrechte.
Impressum Datenschutz Blog Community Feedback Changelog
Im App Store herunterladen Bei Google Play herunterladen
All rights reserved © LCP GmbH 2025